Management of hypoactive sexual desire disorder in women: Current and emerging therapies

Rossella E. Nappi, Ellis Martini, Erica Terreno, Francesca Albani, Valentina Santamaria, Silvia Tonani, Luca Chiovato, Franco Polatti

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Hypoactive sexual desire disorder (HSDD) is a common multifactorial condition which is characterized by a decrease in sexual desire that causes marked personal distress and/ or interpersonal difficulty. The general idea that HSDD is a sexual dysfunction difficult to treat is due to the large number of potential causes and contributing factors. Indeed, a balanced approach comprising both biological and psycho-relational factors is mandatory for accurate diagnosis and tailored management in clinical practice. There are currently no approved pharmacological treatments for premenopausal women with HSDD, while transdermal testosterone is approved in Europe for postmenopausal women who experience HSDD as a result of a bilateral oophorectomy. Even though the role of sex hormones in modulating the sexual response during the entire reproductive life span of women is crucial, a better understanding of the neurobiological basis of sexual desire supports the idea that selective psychoactive agents may be proposed as nonhormonal treatments to restore the balance between excitatory and inhibitory stimuli leading to a normal sexual response cycle. We conclude that the ideal clinical approach to HSDD remains to be established in term of efficacy and safety, and further research is needed to develop specific hormonal and nonhormonal pharmacotherapies for individualized care in women.

Original languageEnglish
Pages (from-to)167-175
Number of pages9
JournalInternational Journal of Women's Health
Volume2
Issue number1
Publication statusPublished - 2010

Fingerprint

Psychological Sexual Dysfunctions
Therapeutics
Psychotropic Drugs
Gonadal Steroid Hormones
Ovariectomy
Testosterone
Pharmacology
Safety
Drug Therapy
Research

Keywords

  • Distress
  • Psychoactive drugs
  • Psychosexual interventions
  • Sexual desire
  • Testosterone

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Maternity and Midwifery

Cite this

Nappi, R. E., Martini, E., Terreno, E., Albani, F., Santamaria, V., Tonani, S., ... Polatti, F. (2010). Management of hypoactive sexual desire disorder in women: Current and emerging therapies. International Journal of Women's Health, 2(1), 167-175.

Management of hypoactive sexual desire disorder in women : Current and emerging therapies. / Nappi, Rossella E.; Martini, Ellis; Terreno, Erica; Albani, Francesca; Santamaria, Valentina; Tonani, Silvia; Chiovato, Luca; Polatti, Franco.

In: International Journal of Women's Health, Vol. 2, No. 1, 2010, p. 167-175.

Research output: Contribution to journalArticle

Nappi, RE, Martini, E, Terreno, E, Albani, F, Santamaria, V, Tonani, S, Chiovato, L & Polatti, F 2010, 'Management of hypoactive sexual desire disorder in women: Current and emerging therapies', International Journal of Women's Health, vol. 2, no. 1, pp. 167-175.
Nappi, Rossella E. ; Martini, Ellis ; Terreno, Erica ; Albani, Francesca ; Santamaria, Valentina ; Tonani, Silvia ; Chiovato, Luca ; Polatti, Franco. / Management of hypoactive sexual desire disorder in women : Current and emerging therapies. In: International Journal of Women's Health. 2010 ; Vol. 2, No. 1. pp. 167-175.
@article{434ae3190ccc4b9a8061a768838db636,
title = "Management of hypoactive sexual desire disorder in women: Current and emerging therapies",
abstract = "Hypoactive sexual desire disorder (HSDD) is a common multifactorial condition which is characterized by a decrease in sexual desire that causes marked personal distress and/ or interpersonal difficulty. The general idea that HSDD is a sexual dysfunction difficult to treat is due to the large number of potential causes and contributing factors. Indeed, a balanced approach comprising both biological and psycho-relational factors is mandatory for accurate diagnosis and tailored management in clinical practice. There are currently no approved pharmacological treatments for premenopausal women with HSDD, while transdermal testosterone is approved in Europe for postmenopausal women who experience HSDD as a result of a bilateral oophorectomy. Even though the role of sex hormones in modulating the sexual response during the entire reproductive life span of women is crucial, a better understanding of the neurobiological basis of sexual desire supports the idea that selective psychoactive agents may be proposed as nonhormonal treatments to restore the balance between excitatory and inhibitory stimuli leading to a normal sexual response cycle. We conclude that the ideal clinical approach to HSDD remains to be established in term of efficacy and safety, and further research is needed to develop specific hormonal and nonhormonal pharmacotherapies for individualized care in women.",
keywords = "Distress, Psychoactive drugs, Psychosexual interventions, Sexual desire, Testosterone",
author = "Nappi, {Rossella E.} and Ellis Martini and Erica Terreno and Francesca Albani and Valentina Santamaria and Silvia Tonani and Luca Chiovato and Franco Polatti",
year = "2010",
language = "English",
volume = "2",
pages = "167--175",
journal = "International Journal of Women's Health",
issn = "1179-1411",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Management of hypoactive sexual desire disorder in women

T2 - Current and emerging therapies

AU - Nappi, Rossella E.

AU - Martini, Ellis

AU - Terreno, Erica

AU - Albani, Francesca

AU - Santamaria, Valentina

AU - Tonani, Silvia

AU - Chiovato, Luca

AU - Polatti, Franco

PY - 2010

Y1 - 2010

N2 - Hypoactive sexual desire disorder (HSDD) is a common multifactorial condition which is characterized by a decrease in sexual desire that causes marked personal distress and/ or interpersonal difficulty. The general idea that HSDD is a sexual dysfunction difficult to treat is due to the large number of potential causes and contributing factors. Indeed, a balanced approach comprising both biological and psycho-relational factors is mandatory for accurate diagnosis and tailored management in clinical practice. There are currently no approved pharmacological treatments for premenopausal women with HSDD, while transdermal testosterone is approved in Europe for postmenopausal women who experience HSDD as a result of a bilateral oophorectomy. Even though the role of sex hormones in modulating the sexual response during the entire reproductive life span of women is crucial, a better understanding of the neurobiological basis of sexual desire supports the idea that selective psychoactive agents may be proposed as nonhormonal treatments to restore the balance between excitatory and inhibitory stimuli leading to a normal sexual response cycle. We conclude that the ideal clinical approach to HSDD remains to be established in term of efficacy and safety, and further research is needed to develop specific hormonal and nonhormonal pharmacotherapies for individualized care in women.

AB - Hypoactive sexual desire disorder (HSDD) is a common multifactorial condition which is characterized by a decrease in sexual desire that causes marked personal distress and/ or interpersonal difficulty. The general idea that HSDD is a sexual dysfunction difficult to treat is due to the large number of potential causes and contributing factors. Indeed, a balanced approach comprising both biological and psycho-relational factors is mandatory for accurate diagnosis and tailored management in clinical practice. There are currently no approved pharmacological treatments for premenopausal women with HSDD, while transdermal testosterone is approved in Europe for postmenopausal women who experience HSDD as a result of a bilateral oophorectomy. Even though the role of sex hormones in modulating the sexual response during the entire reproductive life span of women is crucial, a better understanding of the neurobiological basis of sexual desire supports the idea that selective psychoactive agents may be proposed as nonhormonal treatments to restore the balance between excitatory and inhibitory stimuli leading to a normal sexual response cycle. We conclude that the ideal clinical approach to HSDD remains to be established in term of efficacy and safety, and further research is needed to develop specific hormonal and nonhormonal pharmacotherapies for individualized care in women.

KW - Distress

KW - Psychoactive drugs

KW - Psychosexual interventions

KW - Sexual desire

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=77955536114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955536114&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77955536114

VL - 2

SP - 167

EP - 175

JO - International Journal of Women's Health

JF - International Journal of Women's Health

SN - 1179-1411

IS - 1

ER -